Fintel on MSN15h
Stifel Upgrades Alkermes (ALKS)
Fintel reports that on November 5, 2024, Stifel upgraded their outlook for Alkermes (NasdaqGS:ALKS) from Hold to Buy. Analyst ...
Alkermes raised to buy by Stifel on increased confidence for ALKS2680
Stifel has upgraded Alkermes (ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug candidate ALKS2680. Read more here.